At a glance

Lundbeck in brief

Lundbeck is a global pharmaceutical company specialized in developing innovative treatments for brain diseases. For more than 70 years, millions of people have been treated with our products and our development and distribution of pioneering therapies continues to make a difference to people worldwide.

Lundbeck in numbers

1915

Lundbeck was founded by Hans Lundbeck in Copenhagen more than 100 years ago.

~5,500

We are more than 5,500 employees worldwide.

70%

Our largest shareholder is the Lundbeck Foundation owning approximately 70% of the company.

+80

Our products are registered in more than 80 countries globally.

+70

Number of years that we have been building our neuroscience expertise.

+8 m

Our portfolio of products reaches more than 8 million people on a daily average.

+30

Number of treatments launched by Lundbeck over the years.

Global presence

We are headquartered in Denmark and located in more than 50 countries around the world. We have production facilities in Denmark, France, and Italy, and research centers in Denmark and the U.S.

Total number of employees 2023

We have employees in more than 50 countries, and employ approximately 5,500 people across the value chain.

Ownership

In 1999, Lundbeck’s shares were listed on Nasdaq Copenhagen. Our largest shareholder is the Lundbeck Foundation, which holds approximately 70% of the shares. The Foundation annually grants about DKK 500 million to support medical research and educational and communication activities.

Key financial figures

Our 2023 revenue reached a total of DKK 19.9 billion.

Our largest markets are US, China, Canada, Spain, Italy, France, Japan, Brazil, Australia and South Korea.

Revenue per region 2023

In 2023, our total revenue from strategic brands was DKK 13.7 billion.

Total revenue from key products 2019-2023 (DKKm)